Monitor for topline data from OPUS-1 in Q4 2026, which could be a major catalyst. Until then, no new efficacy or safety data to assess; current market cap reflects future potential, not near-term fundamentals.
PCVX drugs
PCVX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 23 $55.94entry
- T+1 · 8mo ago −2.27%α −1.91% · $54.67
- T+5 · 8mo ago −1.75%α +1.81% · $54.96
- T+20 · 7mo ago +8.24%α +0.82% · $60.55
- T+60 · 5mo ago −9.42%α −22.48% · $50.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vaxcyte announced completion of enrollment in the OPUS-1 and OPUS-2 Phase 3 trials for its investigational 31-valent pneumococcal vaccine VAX-31. Topline data from OPUS-1 is expected in Q4 2026, with OPUS-2 and OPUS-3 results anticipated in H1 2027. The trials are designed to support a future Biologics License Application (BLA) submission to the FDA, building on prior Breakthrough Therapy designation for VAX-31 in preventing invasive pneumococcal disease and pneumonia.
Key Facts
- Enrollment completed in OPUS-1 (n≈4,000) and OPUS-2 (n≈1,300) Phase 3 trials for VAX-31.
- Topline data from OPUS-1 expected in Q4 2026; OPUS-2 and OPUS-3 results expected in H1 2027.
- OPUS-1 is a pivotal noninferiority trial comparing VAX-31 to Capvaxive® (PCV21) and Prevnar 20® (PCV20) in adults ≥50 years.
- VAX-31 has FDA Breakthrough Therapy Designation for prevention of both IPD and pneumococcal pneumonia in adults.
- No clinical results or financial figures reported, this is a program update on trial enrollment.
Financial Impact
No immediate financial impact; potential long-term value if VAX-31 demonstrates superiority and gains approval.
Risk Factors
- Clinical trial results may not meet endpoints despite favorable Phase 1/2 data.
- Regulatory delays or failure to obtain BLA approval even with positive data.
- High market expectations already priced in given $7.9B market cap despite being pre-revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260381 |
Track record
29 reports on PCVX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 20261d ago SC 13G Neutral 3/10 Entry $61.61 Now $61.61 +0.00% settles Dec 15
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $64.69 Now $61.61 −4.76% settles Dec 11
- Nov 6, 202611d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 6, 202611d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
- Nov 4, 202613d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 4, 202613d ago 8-K Neutral 5/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
- Nov 2, 202615d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Nov 2, 202615d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
- Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $61.61 +12.80% ▲ +4.42% +1.15% vs SPY
- Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $61.61 +13.69% ▲ +10.49% +4.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers